Company intelligence / Profile preview

Syndicate Bio

Ownership: Private
Development stage: Commercial

Overview

Syndicate Bio is actively running pilot studies such as "Cancer Genome Nigeria," sequencing oncogenes from patients across diverse Nigerian populations. The company has launched commercial NGS-based diagnostic tests and is expanding access to liquid biopsy testing through partnerships. No interventional drug trials or late-stage therapeutics reported yet.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Next-generation sequencing (NGS)Liquid biopsyGenomic profiling
Industry: Molecular Diagnostics

Partnerships

National Institute for Cancer Research and Treatment (NICRAT), NigeriaSOPHiA GENETICS (for AI-powered liquid biopsy technology)National Institute of Medical Research (NIMR), Nigeria

Beyond the preview

Go deeper on Syndicate Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syndicate Bio.

Explore the full profile